SCHEMBL5450060

SCHEMBL5450060

CCCCCCC(CCC)CCCC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.63
FFAR1 O14842 2/20 0.63
GPR84 Q9NQS5 7/20 0.61
PPARG P37231 7/20 0.61
PPARD Q03181 7/20 0.61
PPARA Q07869 7/20 0.61
HDAC11 Q96DB2 5/20 0.61
TSHR P16473 4/20 0.61
PTPN1 P18031 3/20 0.61
ALDH1A1 P00352 3/20 0.61
TLR2 O60603 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
FABP4 P15090 2/20 0.61
KMT2A Q03164 2/20 0.61
SLC22A6 Q4U2R8 1/20 0.61
SLC22A8 Q8TCC7 1/20 0.61
MEN1 O00255 1/20 0.61
ESR1 P03372 1/20 0.61
ALOX15 P16050 1/20 0.61
PDE4A P27815 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879001 1.00 FFAR4 (0.63) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL26614829 0.98 FFAR4 (0.60) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL2113762 0.96 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL5879088 0.96 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL27917758 0.96 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL5879015 0.96 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL626863 0.96 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL5878798 0.96 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL28767027 0.96 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL27917702 0.96 FFAR4 (0.69) FFAR4FFAR1GPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018122626-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN CELLIX BIO PRIVATE LIMITED (IN) 2018-07-05 WO disclosed
WO-2018096405-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES CELLIX BIO PRIVATE LIMITED (IN) 2018-05-31 WO disclosed
US-20160031935-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF NUCHEM THERAPEUTICS (CA) 2016-02-04 US disclosed
EP-2961765-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF Adaerata, Limited Partnership (CA) 2016-01-06 EP disclosed
WO-2014139008-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF ADAERATA, LIMITED PARTNERSHIP (CA) 2014-09-18 WO disclosed
US-20070036841-A1 Method of enhancing an ornithine-urea cycle in ruminant gut tissues to detoxify ammonia and increase local urea recycling to the rumen for microbial protein synthesis BEQUETTE BRIAN JAMES 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031935-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 FFAR4 1289/4885FFAR1 854/4885GPR84 2314/4885
US-20070036841-A1 Method of enhancing an ornithine-urea cycle in ruminant gut tissues to detoxify ammonia and increase local urea recycling to the rumen for microbial protein synthesis OAT, OTC, ODC1 FFAR4 2541/4885FFAR1 2278/4885GPR84 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.